DESTINY-Breast03 Phase 3 Study Results
Change in Tumor Size over Time in BC Cohorts
Change in Sum of Diameters
From Baseline, %
100
80
60
60
HER2-positive
Treated with T-DXd 5.4 mg/kg in part 1
100-
80
60-
HER2-low
Hormone receptor negative
40
40
20
20
0
-20
-40
-60
T
ד
T
Change in Sum of Diameters
From Baseline, %
40-
20-
0
-20-
-40
-60
-80
-80
-100
-100-
T
T
Baseline 1 2
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Baseline 1 2 3 4 56
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Time From First Dose of Study Drug, months
Cohort 1 HER2 positive (n = 32) (part 1/2: T-DXd 5.4 mg/kg and nivolumab 360 mg)
Time From First Dose of Study Drug, months
Cohort 2 HER2-low (n = 16) (part 2: T-DXd 5.4 mg/kg and nivolumab 360 mg)
BC, breast cancer; HER2, human epidermal growth factor receptor 2; T-DXd, trastuzumab deruxtecan.
2 out of 3 patients with HER2-positive BC treated with T-DXd 5.4 mg/kg RDE in combination with nivolumab 360 mg in Part 1 are shown. 2 out of 3 patients with HER2-low hormone receptor negative BC shown.
ESMO BC 2022 #1620 Oral
Daiichi-Sankyo
66View entire presentation